| Indication : | Dacarbazine for injection is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine for injection is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. |
| Dosage :- | Malignant melanoma : 2-4.5 mg/kg/day for 10 days may be repeated at 4 weeks intervel or 250 mg/ml of body surface area (BSA)/day for 5 days repeated after 3 weeks. Hodgkin's disease : 150mg/m² to be repeated every 15 days. |
| Contra Indications:- | Dacarbazine for injection is contraindicated in patients who have demonstrated a hypersensitivity to it in the past. |
| Precautions:- | Breast-feeding is usually stopped while using anticancer drugs. Dacarbazine should be used only when clearly needed during pregnancy. |
| Drug interaction: | Impairs immune response to vaccines; possible infection after admin of live vaccines. Effect increased by CYP1A2 inhibitors e.g. amiodarone, ciprofloxacin, fluvoxamine, ketoconazole, lomefloxacin, ofloxacin and rofecoxib. Effect decreased by CYP1A2 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital and rifampicin. |
| Adverse effects: | Haemopoietic depression invading mainly leucocytes and platelets anaphylactoid reaction, anorexia, nausea, vomiting, diarrhoea, influneza like syndrome, alopecia, facial flushing, paresthesia, ash liver function and renal function abnormalities |
| Storage: | Store in a refrigerator 2°C to 8°C (36°F to 46°F). dacarbazine Use within 8 hours of reconstitution. Protect from light |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
